Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OFIRMEV vs ENTEREG
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.
Selective 5-HT4 receptor agonist; enhances gastrointestinal motility by increasing peristalsis and accelerating colonic transit.
Management of mild to moderate pain,Management of moderate to severe pain with adjunctive opioid analgesics,Reduction of fever
FDA-approved for the treatment of chronic idiopathic constipation in adults
IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.
Adults: 12 mg orally twice daily for up to 15 days, initiated within 30 minutes prior to surgery and continued postoperatively.
Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels.
Terminal half-life is approximately 10–17 hours in healthy subjects. Clinically, the half-life may be prolonged in severe hepatic impairment but is not significantly altered in renal impairment.
Acetaminophen is primarily metabolized in the liver via conjugation with glucuronide (50-60%) and sulfate (20-30%). A minor amount is oxidized by cytochrome P450 (CYP2E1, CYP1A2, CYP3A4) to a toxic reactive metabolite (NAPQI), which is normally detoxified by glutathione. At toxic doses, glutathione is depleted, leading to NAPQI accumulation and hepatotoxicity.
Primarily metabolized by cytochrome P450 3A4 (CYP3A4); also involves CYP2D6 and CYP2C9 to a lesser extent.
Primarily renal (85% as sulfate and glucuronide conjugates, 10% as unchanged drug). Less than 5% fecal/biliary.
Primarily hepatobiliary excretion; unchanged drug and major metabolite (alvimopan) undergo extensive biliary elimination with fecal excretion accounting for >90% of total elimination. Renal excretion is minimal (<5% as unchanged drug).
10-25% bound to albumin at therapeutic concentrations.
Approximately 80–90% bound to plasma proteins, primarily albumin.
0.8-1.0 L/kg. Indicates distribution into total body water.
Volume of distribution is about 30 L (approximately 0.4 L/kg), indicating distribution into extracellular fluid and tissues.
100% (intravenous); not applicable for other routes as OFIRMEV is IV only.
Oral bioavailability is approximately 6–10% due to extensive first-pass metabolism; the drug is administered orally for local gastrointestinal activity.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, extend dosing interval to every 8 hours; maximum daily dose 3000 mg.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) or dialysis.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce total daily dose by 50% (max 2000 mg/day). Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose to 50% of standard and extend interval to every 8 hours; maximum 2000 mg/day.
No dose adjustment for mild to moderate hepatic impairment (Child-Pugh A or B). Caution in severe hepatic impairment (Child-Pugh C); no specific dose recommendation.
Weight-based: <10 kg: 7.5 mg/kg/dose every 6 hours; 10-50 kg: 15 mg/kg/dose every 6 hours; >50 kg: 1000 mg every 6 hours or 650 mg every 4 hours. Maximum single dose: 15 mg/kg (up to 1000 mg); maximum daily dose: 75 mg/kg (up to 4000 mg).
Not FDA-approved for pediatric patients; safety and efficacy not established.
No specific dose adjustment; consider reduced renal function. For Cr Cl <30 m L/min, extend interval to every 8 hours. Maximum daily dose: 3000 mg in frail elderly or with comorbidities.
No specific dose adjustment; use with caution due to potential increased sensitivity and renal function decline. Monitor for adverse effects.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
No FDA boxed warning.
Risk of serious hepatotoxicity, especially with doses >4000 mg/day or in patients with underlying liver disease,Risk of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) – discontinue at first sign of rash,Risk of hypersensitivity reactions including anaphylaxis,Use caution in patients with severe hepatic impairment, active hepatic disease, or alcoholism,Avoid concurrent use of other acetaminophen-containing products
May cause diarrhea, leading to electrolyte disturbances or hypovolemia,Use with caution in patients with severe renal impairment,Avoid use in patients with a history of mechanical gastrointestinal obstruction, perforation, or severe inflammatory bowel disease
Known hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease (relative contraindication without black box)
Hypersensitivity to prucalopride or any excipients,Renal impairment requiring dialysis,Intestinal obstruction or perforation
No known food interactions. However, avoid excessive alcohol consumption as it may increase the risk of liver damage.
No specific food interactions reported. However, as ENTEREG is administered in a hospital setting, patients should follow the prescribed diet (typically clear liquids advancing to regular diet as tolerated postoperatively). Avoid grapefruit juice as it may affect drug metabolism via CYP3A4 (though not specifically studied, caution is advised).
Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dose use in third trimester may be associated with preterm birth or low birth weight. Avoid prolonged use above recommended doses.
No human data; animal studies at doses up to 10 mg/kg/day in rats and rabbits showed no teratogenicity at exposures lower than human dose; risk cannot be excluded due to lack of adequate human studies.
Acetaminophen is excreted in breast milk in low concentrations (M/P ratio approximately 0.9-1.0). Considered compatible with breastfeeding; peak milk levels occur 1-2 hours after maternal dosing. Use lowest effective dose for shortest duration.
No data on presence in human milk; caution advised; M/P ratio unknown.
No dose adjustment required during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may lead to lower peak concentrations but standard dosing remains effective. Maximum single dose: 1 g; maximum daily dose: 4 g.
No pharmacokinetic studies in pregnancy; dose adjustment not required based on available data.
OFIRMEV (acetaminophen) injection is an IV formulation of acetaminophen used for pain and fever management. It is a prodrug that requires no hepatic conversion, providing rapid onset of action. Monitor for hepatotoxicity; maximum daily dose is 4 grams in adults but lower in patients with hepatic impairment or malnutrition. Do not exceed 1 gram per dose. Hypotension and anaphylaxis have been reported. Not interchangeable with oral acetaminophen due to dose equivalency. Use with caution in patients with alcohol use disorder.
ENTEREG (alvimopan) is a peripherally acting mu-opioid receptor antagonist indicated to accelerate postoperative recovery of GI function after bowel resection surgery. It does not cross the blood-brain barrier, so it does not reverse opioid analgesia. Use is restricted to hospitalized patients; it should not be used for more than 7 days. Contraindicated in patients who have taken therapeutic doses of opioids for >7 consecutive days immediately prior to initiation, as it may precipitate opioid withdrawal. Monitor for GI adverse effects such as nausea, vomiting, and abdominal pain.
OFIRMEV is given intravenously for pain or fever.,Do not take additional acetaminophen-containing medications while receiving OFIRMEV.,Report any signs of allergic reaction (rash, itching, swelling, trouble breathing).,Seek immediate medical attention if you experience severe abdominal pain, yellowing of skin or eyes, or dark urine.,Inform your healthcare provider about all medications you are taking, especially blood thinners.
Take ENTEREG exactly as prescribed; do not take more than the recommended dose.,This medication is used only in the hospital after bowel surgery to help your bowels start working again.,It does not reduce pain or interfere with your pain medication.,Report any severe abdominal pain, nausea, vomiting, or diarrhea to your healthcare provider.,Do not take this medication if you have recently taken opioid pain medications for more than 7 days in a row.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OFIRMEV vs ENTEREG, answered by our medical review team.
OFIRMEV is a Non-opioid Analgesic that works by OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.. ENTEREG is a Peripheral Opioid Antagonist that works by Selective 5-HT4 receptor agonist; enhances gastrointestinal motility by increasing peristalsis and accelerating colonic transit.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OFIRMEV and ENTEREG depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OFIRMEV is: IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.. The standard adult dose of ENTEREG is: Adults: 12 mg orally twice daily for up to 15 days, initiated within 30 minutes prior to surgery and continued postoperatively.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OFIRMEV and ENTEREG in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OFIRMEV is classified as Category C. Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dos. ENTEREG is classified as Category C. No human data; animal studies at doses up to 10 mg/kg/day in rats and rabbits showed no teratogenicity at exposures lower than human dose; risk cannot be excluded due to lack of ad. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.